The European Medicines Agency (EMA) has announced that those who have suffered from capillary leak syndrome should not be vaccinated with AstraZeneca doses. Although there is a small number of cases, the EMA has decided that this pathology be added to the package leaflet as new adverse effect on the Covid-19 vaccine by AstraZeneca.
Apparently, and according to agencies, 6 cases of capillary leak syndrome have been detected in those people who had received this vaccine.
Who has it affected?
A large part of the cases have occurred in women and in the four days after being inoculated with this vaccine. Three of those affected had history of capillary leak syndrome and one of them subsequently passed away.
Although the EMA considers that this effect is very rare, it asks that the effects of capillary leak syndrome be observed well.
What are the symptoms?
The European Medicines Agency itself has explained that whoever has been vaccinated with AstraZeneca and has rapid swelling of the arms and legs or a very sudden weight gain the days after being vaccinated go to the doctor.
Capillary leak syndrome
From the Health website where some adverse effects and their updates are collected, it is explained that systemic capillary leak syndrome is a serious and very rare disorder, characterized by a increased capillary permeability that allows fluid and protein to leak from the circulatory system to the interstitial space, which can lead to shock and massive edema.
They also recommend that health professionals should be alert to the appearance of symptoms suggestive of systemic capillary leak syndrome, especially in people with a history of it, and thereby explain to those vaccinated that they should seek immediate medical attention in case such symptoms appear.
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has ruled on the matter and do not see now causal relationship, and therefore does not link it as a new adverse effect in the AstraZeneca Covid-19 vaccine.
It has clarified that current evidence does not suggest that capillary leak syndrome is caused by this vaccine.
In any case, Spain and the rest of the EU countries are governed by what the EMA dictates. Let us remember that the administration of this vaccine in children under 60 years of age was stopped by the appearance of various thrombi that may or may not be related to the administration of this vaccine.